Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today reported that data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018)
HOUSTON, /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today reported that data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018). The studies describe results achieved using multi-tumor antigen specific T cells that were developed at the Baylor College of Medicine in the laboratories of Dr. Ann Leen and Dr. Juan Vera, and exclusively licensed to Marker. Among the highlights, results from an ongoing Phase 1 study in patients with multiple myeloma will be reviewed in an oral presentation by Premal Lulla, M.B.B.S., Assistant Professor of Medicine at the Center for Cell and Gene Therapy, Hematology-Oncology, at the Baylor College of Medicine. ASH 2018 will take place in San Diego, CA from December 1-4. Oral Presentation Details: Title: Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma (Abstract # 1014) Poster Presentation Details: Title: Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells (Abstract #1685) Title: Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens (Abstract #2693) The presentations will contain results beyond what are available in the abstracts on the ASH website. About Marker Therapeutics, Inc. Marker is also advancing several innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells. For additional information, please call toll free at (904) 862-6490 or visit: markertherapeutics.com. To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/. Follow us on Twitter @MRKRTherapeutic, or follow us on Facebook. Forward-Looking Statement Disclaimer
View original content to download multimedia:http://www.prnewswire.com/news-releases/the-center-for-cell-and-gene-therapy-at-baylor-college-of-medicine-to-present-at-the-60th-american-society-of-hematology-annual-meeting-300756376.html SOURCE Marker Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:MRKR |